Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Xu

Showing results (1111-1120 of 1,148) with videos related to

Pageof 115
Sort By:
Zhonghua Yi Xue Za Zhi|December 12, 2018
[Clinical outcomes with beta-blockers in stable patients undergoing percutaneous coronary intervention with adequate left ventricular ejection function]Y Chen, Y Song, J J Xu, et al.
Zhonghua Yi Xue Za Zhi|June 4, 2020
[The impact of metabolic syndrome and its individual components on long-term prognosis of patients undergoing percutaneous coronary intervention]H H Wang, S D Jia, Y Liu, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|January 24, 2019
[Impact of coronary artery lesion calcification on the long-term outcome of patients with coronary heart disease after percutaneous coronary intervention]Y Zhang, L Song, Y Song, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|May 19, 2022
[Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation]J J Xu, P Zhu, Y Song, et al.
Oncogenesis|January 31, 2017
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancyB Xu, J Lefringhouse, Z Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast CancerB Xu, H Jeong, T Sun, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|March 2, 2019
[Impact of short-time anticoagulant therapy after selective percutaneous intervention on prognosis of patients with coronary artery disease]Y Song, X F Tang, J J Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2025
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 studyB Pistilli, K Jhaveri, S-A Im, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|July 25, 2017
[Outcome analysis of patients undergoing percutaneous coronary intervention with or without prior coronary artery bypass grafting operation]Y Song, J J Xu, X F Tang, et al.
Pageof 115

Showing results (1111-1120 of 1,148) with videos related to

Sort By:
Pageof 115
Zhonghua Yi Xue Za Zhi|December 12, 2018
[Clinical outcomes with beta-blockers in stable patients undergoing percutaneous coronary intervention with adequate left ventricular ejection function]Y Chen, Y Song, J J Xu, et al.
Zhonghua Yi Xue Za Zhi|June 4, 2020
[The impact of metabolic syndrome and its individual components on long-term prognosis of patients undergoing percutaneous coronary intervention]H H Wang, S D Jia, Y Liu, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|January 24, 2019
[Impact of coronary artery lesion calcification on the long-term outcome of patients with coronary heart disease after percutaneous coronary intervention]Y Zhang, L Song, Y Song, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|May 19, 2022
[Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation]J J Xu, P Zhu, Y Song, et al.
Oncogenesis|January 31, 2017
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancyB Xu, J Lefringhouse, Z Liu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast CancerB Xu, H Jeong, T Sun, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|March 2, 2019
[Impact of short-time anticoagulant therapy after selective percutaneous intervention on prognosis of patients with coronary artery disease]Y Song, X F Tang, J J Xu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2025
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 studyB Pistilli, K Jhaveri, S-A Im, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|July 25, 2017
[Outcome analysis of patients undergoing percutaneous coronary intervention with or without prior coronary artery bypass grafting operation]Y Song, J J Xu, X F Tang, et al.
Pageof 115